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Background
Glioblastoma (GBM) is a poorly immunogenic neoplasm
treated with local radiation. Despite the standard of care,
median survival remains low. Immunotherapy has syner-
gized with stereotactic radiosurgery (SRS) in murine
GBM, as radiation promotes a pro-inflammatory tumor
microenvironment amenable to the anti-tumor effects of
immune modulation. Glucocorticoid-induced tumor
necrosis factor receptor (GITR) is a co-stimulatory recep-
tor expressed constitutively on regulatory T cells and
inducibly on effector T cells. We tested the hypothesis
that anti-GITR monoclonal antibody (mAb) and SRS com-
bination therapy would confer immune-mediated survival
benefit in murine glioma.
Methods
Mice were implanted with GL261-luc murine glioma cells
and began SRS and anti-GITR IgG1 treatment after
10 days. Mice were randomized to four treatment groups:
control, SRS only, anti-GITR only, anti-GITR+SRS. SRS
was delivered to the tumor in one fraction; mice were
given mAb thrice i.p. Mice were euthanized on day 21 to
analyze the immunologic profile of tumor, spleen, and
tumor draining lymph nodes.
Results
Anti-GITR mAb plus SRS conferred significantly
improved survival over either treatment alone (p < .0001,
cure rate 24%). The increased survival required CD4+T
cells but not CD8+T cells or regulatory T cells (Tregs).
There was elevated intratumoral CD4+ effector-cell infil-
tration (CD4+/Foxp3-/IFNg+) relative to Treg infiltration
(CD4+/Foxp3+) at day 21 in mice treated with anti-GITR
+SRS, and significantly elevated IFNg and IL-2 production
by CD4+T cells and elevated IFNg and TNFa production
by CD8+T cells. Intratumoral mononuclear cells demon-
strated increased mRNA expression of pro-inflammatory
M1 markers and decreased expression of immunosuppres-
sive M2 markers.
Conclusions
In all, anti-GITR mAb synergizes with SRS to significantly
prolong survival in murine orthotopic glioma in a poten-
tially CD4+ Th1-dominant anti-tumor mechanism with
M1 polarization. These findings provide preclinical
evidence for the use of anti-GITR IgG1 non-depleting
antibodies alongside SRS in human GBM.
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